Chemical formula: C₁₈H₂₃FO₂ Molecular mass: 289.381 g/mol
Fluoroestradiol ¹⁸F binds estrogen receptor (ER) and is indicated for use with positron emission tomography (PET imaging) for characterization of ER status of known or suspected metastatic lesions in patients with confirmed ER-positive breast cancer.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V09IX11 | V Various → V09 Diagnostic radiopharmaceuticals → V09I Tumour detection → V09IX Other diagnostic radiopharmaceuticals for tumour detection | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| CERIANNA Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Fluoroestradiol ¹⁸F is an active ingredient of these brands:
United States (US)France (FR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
